Table S2.
Clinical trial: Baseline characteristics of ALS patients
| Characteristic | PEA-treated group (n = 28) | Untreated group (n = 36) | P |
| Male/female | 16/12 | 19/17 | >0.05 |
| Spinal/bulbar | 24/4 | 30/6 | >0.05 |
| Mean age at onset, y ± SD | 62.3 ± 9.2 | 60.1 ± 9.9 | >0.05 |
| Mean age at enrollment, y ± SD | 65.4 ± 10.0 | 62.0 ± 9.3 | >0.05 |
| Mean FVC, % predicted ± SD | 73.5 ± 16.3 | 77.1 ± 19.3 | >0.05 |
| Disease duration, months ± SD | 35.4 ± 21.6 | 28.5 ± 17.2 | >0.05 |
| Mean ALSFRS-R score ± SD | 36.6 ± 5.1 | 35.0 ± 6.8 | >0.05 |
| Mean MRC score ± SD | 28.3 ± 10.0 | 31.1 ± 8.4 | >0.05 |
| Mean ulnar nerve CMAP ± SD | 6.4 ± 4.3 | 6.4 ± 4.5 | >0.05 |
| Mean phrenic nerve CMAP amplitude ± SD | 0.5 ± 0.3 | 0.6 ± 0.4 | >0.05 |
ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale–revised; CMAP, compound muscle action potentials; FVC, forced vital capacity; MRC, Medical Research Council; PEA, palmitoylethanolamide.